Invion Stock

Invion EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Invion (IVX.AX) as of Aug 26, 2026 is -2.34. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -2.10 — a change of 11.20% (lower).

EV/FCF

-2.34

YoY

11.20%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Invion is 2026 -2.34 . EV/FCF (Enterprise Value to Free Cash Flow) of Invion was 2025 -2.10 . It decreases by 11.20% lower compared to the previous year.

The Invion EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
5.75 AUD
Jan 1, 2019
-2.92 AUD
Jan 1, 2020
-41.43 AUD
Jan 1, 2021
14.12 AUD
Jan 1, 2022
0.18 AUD
Jan 1, 2023
-1.58 AUD
Jan 1, 2024
-2.10 AUD
Jan 1, 2025
-2.34 AUD
The Invion EV/FCF history
YEAREV/FCFYoY
-2.34+11.20%
-2.10+32.93%
-1.58-960.30%
0.18-98.70%
14.12-134.07%
-41.43+1,319.04%
-2.92-150.77%
5.75-119.53%
-29.45+1,365.67%
-2.01+200.55%
-0.67-55.38%
-1.50
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

EV/FCF (Enterprise Value to Free Cash Flow) of Invion is -2.34 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Invion changed from -2.10 to -2.34, representing a 11.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Invion since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Invion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Invion

All Key Metrics — Invion